About 510 results

ALLMedicine™ Superior Vena Cava Syndrome Center

Research & Reviews  190 results

O-12: Non Convectional Vascular Accesses for Treatment of Total Superior Vena Cava Synd...
Transplantation L PI, D R et. al.

Nov 19th, 2021 - O-12: Non Convectional Vascular Accesses for Treatment of Total Superior Vena Cava Syndrome Occlusion in Patients with Type Iii Intestinal Failure.|2021|L PI,D R,L V,C G,D A,|

Percutaneous Endovascular Stent Placement for Treatment of Malignant Superior Vena Cava...
Annals of Vascular Surgery; Wu Y, Li Y et. al.

Nov 16th, 2021 - We assessed the safety as well as the efficacy of self-expanding stent placement for the treatment of malignant superior vena cava syndrome (SVCS), besides identifying the predictable probable factors for the clinical improvement of endovascular s...

Hodgkin Lymphoma

Nov 9th, 2021 - Practice Essentials Hodgkin lymphoma is a potentially curable lymphoma. The World Health Organization classifies Hodgkin lymphoma into the following types [1, 2] : Nodular sclerosing Mixed cellularity (see the image below) Lymphocyte depleted Lymp...

Toxic Nodular Goiter Clinical Presentation

Oct 25th, 2021 - History Thyrotoxic symptoms Most patients with toxic nodular goiter (TNG) present with symptoms typical of hyperthyroidism, including heat intolerance, palpitations, tremor, weight loss, hunger, and frequent bowel movements. Elderly patients may h...

Azygos Vein Central Venous Access in a Patient with Thoracic Central Venous Obstruction.
Annals of Vascular Surgery; Santini A, Veith C et. al.

Oct 14th, 2021 - This is a report of a 45-year-old female with thoracic central venous obstruction (TCVO) and alpha-1 antitrypsin deficiency requiring an implanted port for infusions. The azygos vein was used for catheter access in the setting of an occluded right...

see more →

Clinicaltrials.gov  1 results

Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC

Nov 20th, 2007 - Criteria for inclusion Signed written informed consent Male or female ≥18 years of age Cito-histological diagnosis of NSCLC, stage IV Performance Status = 0 or 1 Measurable disease on CT scan - RECIST criteria White blood count ≥ 3 x 109/L, Neutro...

see more →

News  13 results

Novel Molecular Targets for Drug Development in Non-GIST Sarcomas

Dec 20th, 2020 - William D. Tap, MD Abstract The characterization of molecular abnormalities implicated in the tumorigenesis of sarcomas is being increasingly applied to the classification, prognostication and, in particular situations, management of these ...

From a Distance: Managing Side Effects in Outpatients

Dec 5th, 2020 - Oncology nurses know the intricacies of cancer treatment. They know how to interact with patients in distress. And they know how to handle long-distance relationships. It is a skill nurses have developed in the past 10 years, as cancer treatment h...

Untreated Goiters Larger at Surgery in Men, Minorities, and the Old

Mar 14th, 2016 - Significant disparities exist in the presentation and outcomes of patients with goiters in the United States, with minority ethnic groups, men, and older patients more likely to present with untreated goiters that have become so large they extend ...

David Henry's JCSO podcast, November 2014
Dr. David Henry

Nov 30th, 2014 - Among the items featured in Dr David Henry’s monthly podcast for The Journal of Community and Supportive Oncology, are reports on congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leuke.

Superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma
Shakira Grant et al

Nov 17th, 2014 - Superior vena cava (SVC) syndrome refers to a constellation of symptoms produced by the obstruction of blood flow through the SVC, resulting in symptoms of dyspnea, facial and upper-extremity edema, cough, chest pain, and dysphagia. 1 Malignancies.

see more →